fda approved glp-1 receptor agonists Pharmacovigilance Assessment of Compounded Agonists: Insights From the Adverse Event Reporting System diarrhea semaglutide Semaglutide is a

Furthermore, in an internet survey of former statin users, 60% reported SAMSs, and 62% reported discontinuation of statin due to side effects [78]

Our previous work has shown that GLP-1 RAs make up 5% of prescriptions within the US (although this trend has increased, as seen in the latest GLP-1 prescribing and dispense report)

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)

2) direct modulation of cell proliferation and apoptosis

Clinical trials demonstrate that patients receiving liraglutide showed 18% slower cognitive decline over one year compared to placebo 30

Safety analysis showed no increased risk of infections (SGLT2i) or pancreatitis (GLP-1RAs)